Results 1 to 10 of about 286,662 (351)
Reduction of cyclophosphamide dose for patients with subset 2 low‐risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group
Cancer, 2017 D. Walterhouse, A. Pappo, J. Meza, J. Breneman, A. Hayes-Jordan, D. Parham, T. Cripe, James R. Anderson, William H. Meyer, D. Hawkins +9 moresemanticscholar +1 more sourceInvasive Lobular Carcinoma Metastasis to the Female Genital Tract: A Systematic Search and Review of Case Reports and Case Series. [PDF]
Diagnostics (Basel)Koufopoulos NI, Pouliakis A, Samaras MG, Skarentzos K, Nastos T, Boutas I, Kontogeorgi A, Zanelli M, Palicelli A, Zizzo M, Broggi G, Caltabiano R, Salzano S, Goutas D, Pateras IS, Syrios J, Psyrri A, Arkadopoulos N, Panayiotides IG. +18 moreeuropepmc +1 more sourceAddition of Dendritic Cell Vaccination to Conditioning Cyclophosphamide and Chemoembolization in Patients with Hepatocellular Carcinoma: The ImmunoTACE Trial. [PDF]
Clin Cancer ResMa YT, Zuo J, Kirkham A, Curbishley S, Blahova M, Rowe AL, Bathurst C, Mehrzad H, Karkhanis S, Punia P, James MW, Stern N, Rao A, Hull D, Lowe F, Sylla P, Webster L, Hussain S, Yap C, Palmer D, Adams DH. +20 moreeuropepmc +1 more sourceMultipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
Nature Network Boston, 2012 S. Walter, T. Weinschenk, A. Stenzl, R. Zdrojowy, A. Płużańska, C. Szczylik, M. Staehler, W. Brugger, P. Dietrich, R. Mendrzyk, N. Hilf, O. Schoor, J. Fritsche, A. Mahr, D. Maurer, Verona Vass, C. Trautwein, Peter Lewandrowski, C. Flohr, H. Pohla, J. Stańczak, V. Bronte, S. Mandruzzato, T. Biedermann, G. Pawelec, E. Derhovanessian, H. Yamagishi, T. Miki, F. Hongo, N. Takaha, K. Hirakawa, Hiroaki Tanaka, S. Stevanović, J. Frisch, A. Mayer-Mokler, A. Kirner, H. Rammensee, C. Reinhardt, H. Singh-Jasuja +38 moresemanticscholar +1 more source